Bioventus (BVS) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Bioventus

NasdaqGS•Healthcare•Medical Devices

$12.98-0.08(-0.01%)Pre-market

Market Cap

$857.19M

P/E

15.7x

P/S

1.5x

P/B

3.8x

Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company's restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.

How this company scores

GoodMetricSide Score: 77/100

Strongest: Cash & Earnings Quality (24/25); weakest: Balance Sheet & Red Flags (14/25).

Profitability23/25

Growth16/25

Balance Sheet & Red Flags14/25

Cash & Earnings Quality24/25

Strengths

Rising free cash flowHigh ROERising earningsCash-backed earnings

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 15.7x5y range 15.7x – 57.0x

Currently below its 5-quarter median.

P/S · 1.5x5y range 0.1x – 1.8x

Currently above its 19-quarter median.

P/B · 3.8x5y range 0.4x – 5.1x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

Some Concerns

Earnings Quality

Watch

FCF/Net Income has dropped below 0.7x in 3 quarters — monitor for earnings quality deterioration.

Share Dilution

Watch

Shares outstanding rose 4.0% — mild dilution. Compare to earnings growth to assess the net per-share impact.

Price & Volume

Market Cap $857.19M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $581.85M
Q. Revenue: $153.21M
TTM EBITDA: $104.23M
TTM Op. Income: $58.28M
Q. Op. Income: $19.13M
TTM Net Income: $54.46M
Q. Net Income: $33.44M
EPS: $0.49
Shares Out.: $67.87M

$581.85M in TTM revenue grew 3.1% YoY, reaching $153.21M last quarter. TTM EBITDA of $104.23M and TTM operating income of $58.28M show growth is flowing through to the bottom line. TTM net income of $54.46M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 3 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 69.0%
EBITDA Margin: 13.2%
Op. Margin: 12.5%
Net Margin: 21.8%

Op. margin of 12.5% is up 0.0% YoY — cost efficiency is improving. Net margin at 21.8% and gross margin of 69.0% show how much of each revenue dollar survives to profit. Over the past year, operating margin is up 0% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 15.7x
P/S Ratio: 1.5x
P/B Ratio: 3.8x

At 15.7x P/E, the stock trades within typical market levels. P/S of 1.5x and P/B of 3.8x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Across the last 4 quarters, P/E has fallen for 3 consecutive quarters — an improving trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $673.35M
Cash: $29.46M
Long-Term Debt: $229.70M
Book Value: $228.31M
D/E Ratio: 1.0
Debt/EBITDA: 11.4

With $673.35M in assets and $229.70M in long-term debt, D/E is 1.0and book value is $228.31M — moderate leverage. Across the last 8 quarters, debt/equity has fallen for 3 consecutive quarters — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $19.87M
TTM Free Cash Flow: $94.29M
FCF Margin: 16.2%
FCF / Net Income: 1.7

TTM FCF of $94.29M on $19.87M in operating cash flow. The FCF / Net Income ratio of 1.7x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is up 177% — a weakening trend.